LONDON (dpa-AFX) - GSK plc (GSK.L, GSK) announced the DREAMM-3, the phase III head-to-head superiority trial of Blenrep monotherapy versus pomalidomide in combination with low dose dexamethasone in patients with relapsed or refractory multiple myeloma, did not meet its primary endpoint of progression-free survival. The safety and tolerability profile of belantamab mafodotin was consistent with the known safety profile, the company noted.
Blenrep was granted accelerated approval by the FDA as a monotherapy for treating adult patients with refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The accelerated approval was based on the results of the DREAMM-2 overall response rate, duration of response and contingent upon a confirmed clinical benefit from a randomised phase III trial.
The Group noted that additional trials within the DREAMM clinical trial programme will continue.
For More Such Health News, visit rttnews.com.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX